Cargando…

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

BACKGROUND: Criteria, including clinical features and effective outcomes, for access and persistence of novel but costly treatments may vary between countries, thus affecting the health of patients. Monoclonal antibodies against the calcitonin gene-related peptide pathway (anti-CGRP mAbs) for migrai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iannone, Luigi Francesco, Fattori, Davide, Benemei, Silvia, Chiarugi, Alberto, Geppetti, Pierangelo, De Cesaris, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863684/ https://www.ncbi.nlm.nih.gov/pubmed/35146696 http://dx.doi.org/10.1007/s40263-021-00893-y

Ejemplares similares

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report
por: Iannone, Luigi Francesco, et al.
Publicado: (2021)

Emerging Pharmacological Treatments for Migraine in the Pediatric Population
por: Iannone, Luigi Francesco, et al.
Publicado: (2022)

Antidromic vasodilatation and the migraine mechanism
por: Geppetti, Pierangelo, et al.
Publicado: (2011)

P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment
por: Rossi, Eleonora, et al.
Publicado: (2015)

TRPA1 and other TRP channels in migraine
por: Benemei, Silvia, et al.
Publicado: (2013)

Low-dose methadone for refractory chronic migraine accompanied by medication-overuse headache: a prospective cohort study
por: Benemei, Silvia, et al.
Publicado: (2020)

Reply to Elliot Shevel
por: Geppetti, Pierangelo, et al.
Publicado: (2012)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Protocol and methods for testing the efficacy of well-being therapy in chronic migraine patients: a randomized controlled trial
por: Mansueto, Giovanni, et al.
Publicado: (2018)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

Migraine Treatment: Towards New Pharmacological Targets
por: Silvestro, Marcello, et al.
Publicado: (2023)

Migraine-provoking substances evoke periorbital allodynia in mice
por: De Logu, Francesco, et al.
Publicado: (2019)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

Disability and migraine: MIDAS
por: D’Amico, Domenico, et al.
Publicado: (2001)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

P057. Prophylaxis with low-dose methadone in patients affected by daily refractory headache and medication-overuse headache: a prospective cohort study (METACEF study)
por: Lupi, Chiara, et al.
Publicado: (2015)

Acetaldehyde via CGRP receptor and TRPA1 in Schwann cells mediates ethanol-evoked periorbital mechanical allodynia in mice: relevance for migraine
por: Landini, Lorenzo, et al.
Publicado: (2023)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Cataract in chronic cluster headache: two case reports and review of the literature
por: Benemei, Silvia, et al.
Publicado: (2008)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire
por: Carvalho, Gabriela F., et al.
Publicado: (2021)

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gk2s689ujgcvol0iosmb8jt507